



Verastem to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

July 6, 2016

BOSTON--(BUSINESS WIRE)--Jul. 6, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Wednesday, July 13th at 3:30 PM Eastern Time at Le Parker Meridien New York.

A live audio webcast of the presentation will be available on the company's website at www.verastem.com. An archived presentation will be available for 90 days.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Our product candidates utilize a multi-faceted approach to treat cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and modulating the local tumor microenvironment. Our most advanced clinical product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584. For more information, please visit www.verastem.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160706005455/en/>

Source: Verastem, Inc.

Verastem, Inc.

Brian Sullivan, 781-292-4214

bsullivan@verastem.com